HOME > BUSINESS
BUSINESS
- JCR’s Hunter Syndrome Drug Earns Orphan Status in Europe
March 1, 2019
- Mitsubishi Tanabe, Servier Tie Up on Tenelia Promotion in China
March 1, 2019
- EMA Accepts Astellas’ AML Drug Xospata for Review, Approval Could Come This Summer
March 1, 2019
- Takeda, Aflac, 6 Other Firms to Develop Insurance with Healthy Living Rewards in 1st Shonan Initiative
February 28, 2019
- Pfizer Transferring MA/Distribution Rights for 3 Off-Patent Brands to Teikoku Seiyaku
February 28, 2019
- Ono Files Parkinson’s Drug Opicapone in Japan
February 28, 2019
- Eisai to Fund Japan NGO for Prevention of Infectious Diseases in Sudan
February 28, 2019
- Ono’s Braftovi/Mektovi Combo, Demser Now Available; Takeda’s Fibroid Drug to Hit Shelves on March 1
February 27, 2019
- BMS Seeks Japan Approval for New Empliciti Triplet
February 27, 2019
- Lonsurf Gets Gastric Cancer Nod in US
February 27, 2019
- AbbVie Files Japan NDA for Oral JAK Inhibitor
February 27, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Kowa’s Biz Realignment Reflects Globalization, Workstyle Reform, but No Job Cull Planned: President
February 27, 2019
- Roche Diagnostics Files PD-L1 Expression Assay for Use in Breast Cancer in Japan
February 27, 2019
- FunPep Gets Green Light for Clinical Study in Australia of Antibody-Inducing Peptide for Psoriasis
February 27, 2019
- Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
- Epclusa Hits Japan Market, 1st Drug for Hep C with Decompensated Cirrhosis
February 26, 2019
- Kentaro Murakawa Named as New President for Daiichi Sankyo Espha
February 26, 2019
- Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
- Shionogi Grabs European Nod for Naldemedine
February 25, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
